题名

Role of gut microbiota metabolism and biotransformation on dietary natural products to human health implications with special reference to biochemoinformatics approach

DOI

10.1016/j.jtcme.2022.03.005

作者

Mohd Hafizur Rehman Ansari；Sadia Saher；Rabea Parveen；Washim Khan；Imran Ahmad Khan；Sayeed Ahmad

关键词

Gut microbiota ； Dietary natural compounds ； Gut-microbial diversity ； Mutualism strategies ； GMM-GMBTs reactions ； Bio-chemoinformatics ； Gut microbiota-interplay disorders

期刊名称

Journal of Traditional and Complementary Medicine

卷期/出版年月

13卷2期（2023 / 03 / 01）

页次

150 - 160

内容语文

英文
中文摘要

Gut microbiota contributes to diverse mammalian processes including the metabolic functions of drugs. It is a potential new territory for drug targeting, especially for dietary natural compounds such as tannins, flavonoids, steroidal glycosides, anthocyanins, lignans, alkaloids, and others. Because most herbal medicines are orally administered, the chemical profile and corresponding bioactivities of herbal medicines may be altered and implication to ailments by specific microbiota through gut microbiota metabolisms (GMMs) and gut microbiota biotransformations (GMBTs). In this review, briefly introducing the interactions between different categories of natural compounds and gut microbiota produced countless microbial degraded or fragmented metabolites with their biological significance in rodent-based models. From natural product chemistry division, thousands of molecules are produced, degraded, synthesized, and isolated from natural sources but exploited due to lack of biological significance. In this direction, we add a Bio-Chemoinformatics approach to get clues of biology through a specific microbial assault to (Natural products) NPs.
主题分类 醫藥衛生 > 中醫藥學
参考文献
  1. Ahlström, MM,Ridderström, M,Zamora, I,Luthman, K(2007).CYP2C9 Structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.J Med Chem,50(18),4444-4452.
  2. Ansari, MHR,Khan, W,Parveen, R,Saher, S,Ahmad, S(2022).Pharmacokinetic, metabolomic, and stability assessment of ganoderic acid h based triterpenoid enriched fraction of Ganoderma lucidum P. Karst.Metabolites,12(2),97.
  3. Anwar, S,Bhandari, U,Panda, BP,Dubey, K,Khan, W,Ahmad, S(2018).Trigonelline inhibits intestinal microbial metabolism of choline and its associated cardio-vascular risk.J Pharm Biomed Anal,159,100-112.
  4. Balskus, EP(2015).Colibactin: understanding an elusive gut bacterial genotoxin.Nat Prod Rep,32(11),1534-1540.
  5. Blasco, T,Pérez-Burillo, S,Balzerani, F(2021).An extended reconstruction of human gut microbiota metabolism of dietary compounds.Nat Commun,12(1),4728.
  6. Chang, TS,Ko, HH,Wang, TY,Lee, C-H,Wu, J-Y(2018).Biotransformation of ganoderic acid a to 3-o-acetyl ganoderic acid a by soil-isolated streptomyces sp.Fermentation,4(4),101.
  7. Chen, H,Hayek, S,Rivera, Guzman, J(2012).The microbiota is essential for the generation of black tea theaflavins-derived metabolites.PLoS One,7(12),e51001.
  8. Donia, MS,Fischbach, MA(2015).Small molecules from the human microbiota.Science,349(6246),1254766-1254766.
  9. Dornisch, E,Pletz, J,Glabonjat, RA(2017).Biosynthesis of the enterotoxic pyro-lobenzodiazepine natural product tilivalline.Angew Chem Int Ed.,56(46),14753-14757.
  10. Ekins, S,Mestres, J,Testa, B(2007).In silico pharmacology for drug discovery: applications to targets and beyond.Br J Pharmacol,152(1),21-37.
  11. Espín, JC,González-Sarrías, A,Tomás-Barberán, FA(2017).The gut microbiota: a key factor in the therapeutic effects of (poly)phenols.Biochem Pharmacol,139,82-93.
  12. Glenwright, AJ,Pothula, KR,Bhamidimarri, SP(2017).Structural basis for nutrient acquisition by dominant members of the human gut microbiota.Nature,541(7637),407-411.
  13. Guo, CJ,Chang, FY,Wyche, TP(2017).Discovery of reactive microbiota-derived metabolites that inhibit host proteases.Cell,168(3),517-526.
  14. Haiser, HJ,Turnbaugh, PJ(2013).Developing a metagenomic view of xenobiotic metabolism.Pharmacol Res,69(1),21-31.
  15. Iebba, V,Totino, V,Gagliardi, A(2016).Eubiosis and dysbiosis: the two sides of the microbiota.New Microbiol,39(1),1-12.
  16. Jia, W,Li, H,Zhao, L,Nicholson, JK(2008).Gut microbiota: a potential new territory for drug targeting.Nat Rev Drug Discov.,7(2),123-129.
  17. Karabin, M,Hudcova, T,Jelinek, L,Dostalek, P(2015).Biotransformations and biological activities of hop flavonoids.Biotechnol Adv,33(6),1063-1090.
  18. Kawabata, K,Yoshioka, Y,Terao, J(2019).Role of intestinal microbiota in the bioavailability and physiological functions of dietary polyphenols.Molecules,24(2),370.
  19. Krishnan, S,Ding, Y,Saedi, N(2018).Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages.Cell Rep,23(4),1099-1111.
  20. Kutschera, M,Engst, W,Blaut, M,Braune, A(2011).Isolation of catechin-converting human intestinal bacteria.J Appl Microbiol,111(1),165-175.
  21. Lampe, J,Chang, J(2007).Interindividual differences in phytochemical metabolism and disposition.Semin Cancer Biol,17(5),347-353.
  22. Lanevskij, K,Dapkunas, J,Juska, L,Japertas, P,Didziapetris, R(2011).QSAR analysis of blood-brain distribution: the influence of plasma and brain tissue binding.J Pharmacol Sci.,100(6),2147-2160.
  23. Li, K,Zhuo, C,Teng, C(2016).Effects of Ganoderma lucidum polysaccharides on chronic pancreatitis and intestinal microbiota in mice.Int J Biol Macromol,93,904-912.
  24. McFadden, R-MT,Larmonier, CB,Shehab, KW(2015).The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention.Inflamm Bowel Dis,21(11),2483-2494.
  25. Milshteyn, A,Colosimo, DA,Brady, SF(2018).Accessing bioactive natural products from the human microbiome.Cell Host Microbe,23(6),725-736.
  26. Monagas, M,Urpi-Sarda, M,Sánchez-Patán, F(2010).Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites.Food Funct,1(3),233.
  27. Palmer, C,Bik, EM,DiGiulio, DB,Relman, DA,Brown, PO(2007).Development of the human infant intestinal microbiota.PLoS Biol,5(7),e177.
  28. Paramashivam, SK,Elayaperumal, K,Natarajan, B,Ramamoorthy, M,Balasubramanian, S,Dhiraviam, K(2015).In silico pharmacokinetic and molecular docking studies of small molecules derived from Indigofera aspalathoides Vahl targeting receptor tyrosine kinases.Bioinformation,11(2),73-84.
  29. Pirillo, A,Catapano, AL(2015).Berberine, a plant alkaloid with lipid- and glucoselowering properties: from in vitro evidence to clinical studies.Atherosclerosis,243(2),449-461.
  30. Qiu, M,Huang, K,Liu, Y(2019).Modulation of intestinal microbiota by glycyrrhizic acid prevents high-fat diet-enhanced pre-metastatic niche formation and metastasis.Mucosal Immunol,12(4),945-957.
  31. Raman, M,Ahmed, I,Gillevet, PM(2013).Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol,11(7),868-875.
  32. Sassone-Corsi, M,Nuccio, SP,Liu, H(2016).Microcins mediate competition among Enterobacteriaceae in the inflamed gut.Nature,540(7632),280-283.
  33. Schluter, J,Foster, KR(2012).The evolution of mutualism in gut microbiota via host epithelial selection.PLoS Biol,10(11),e1001424.
  34. Selma, MV,Beltran, D,García-Villalba, R,Espín, JC,Tomás-Barberan, FA(2014).Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species.Food Funct,5(8),1779-1784.
  35. Shen, L,Ji, HF(2019).Bidirectional interactions between dietary curcumin and gut microbiota.Crit Rev Food Sci Nutr,59(18),2896-2902.
  36. Spanogiannopoulos, P,Bess, EN,Carmody, RN,Turnbaugh, PJ(2016).The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.Nat Rev Microbiol,14(5),273-287.
  37. Tan, S,Caparros-Martin, JA,Matthews, VB(2018).Isoquercetin and inulin synergistically modulate the gut microbiome to prevent development of the metabolic syndrome in mice fed a high fat diet.Sci Rep,8(1),10100.
  38. Vijayakumar, BG,Ramesh, D,Joji, A,Jayachandra prakasan, J,Kannan, T(2020).In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2.Eur J Pharmacol,886,173448.
  39. Wang, HY,Qi, LW,Wang, CZ,Li, P(2011).Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides.Am J Chin Med,39(06),1103-1115.
  40. Wang, J,Feng, W,Tang, F,Ao, H,Peng, C(2019).Gut microbial transformation, a potential improving factor in the therapeutic activities of four groups of natural compounds isolated from herbal medicines.Fitoterapia,138,104293.
  41. Wang, K,Feng, X,Chai, L,Cao, S,Qiu, F(2017).The metabolism of berberine and its contribution to the pharmacological effects.Drug Metab Rev,49(2),139-157.
  42. Wang, LQ(2002).Mammalian phytoestrogens: enterodiol and enterolactone.J Chromatogr B.,777(1-2),289-309.
  43. Wang, S,Huang, X-F,Zhang, P(2016).Chronic rhein treatment improves recognition memory in high-fat diet-induced obese male mice.J Nutr Biochem,36,42-50.
  44. Wu, C,Liu, Y,Yang, Y(2020).Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.Acta Pharm Sin B.,10(5),766-788.
  45. Wu, J,Li, Q,Wang, X(2013).Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway.PLoS One,8(3),e59843.
print cancel